Estimating the cost of university-based outbreaks of serogroup B meningococcal disease with different pre-matriculation vaccination policies in the United States

J Am Coll Health. 2024 Dec;72(9):3439-3448. doi: 10.1080/07448481.2022.2163854. Epub 2023 Jan 26.

Abstract

Objective: We developed an Excel-based cost calculator to assess the economic burden of university-based Neisseria meningitidis serogroup B (MenB) outbreaks. Participants: Hypothetical university with 6,354 students. Methods: Total societal costs of outbreak were estimated for three MenB pre-matriculation immunization policies-vaccination required, vaccination recommended, and no vaccine policy-under three different cost assumptions (low/mid-range/high cost). Results: Mid-range cost estimates of an outbreak under "no policy" were $2.60 and $2.70 million (of which 35% were incurred by the university) if targeting all undergraduates for mass vaccination with a two-/three-dose vaccine, respectively. The "required" and "recommended" policies lowered the burden to $2.17-$2.18 million and $2.34-$2.39 million, respectively. For a larger university with 40,000 students, costs were almost $9 million for a two-dose vaccine with "no policy" in place. Conclusions: The economic burden of a university MenB outbreak is substantial, but could be mitigated by a pre-matriculation MenB vaccination requirement or recommendation.

Keywords: Cost calculator; IMD; meningococcal serogroup B; university outbreak; vaccination guidelines.

MeSH terms

  • Disease Outbreaks* / economics
  • Disease Outbreaks* / prevention & control
  • Female
  • Humans
  • Male
  • Meningococcal Infections* / economics
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / prevention & control
  • Meningococcal Vaccines* / economics
  • Neisseria meningitidis, Serogroup B*
  • Students* / statistics & numerical data
  • United States / epidemiology
  • Universities / economics
  • Universities / statistics & numerical data
  • Vaccination / economics
  • Vaccination / statistics & numerical data
  • Young Adult

Substances

  • Meningococcal Vaccines